Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY)

Market Context

Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $165.00 with a market capitalization of $44.2B. The stock has declined 65.7% over the past 52 weeks.

Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alnylam Pharmaceuticals, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Alnylam Pharmaceuticals, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 30, 2026	RBC Capital	Outperform	N/A
Oct 30, 2026	Wells Fargo	Equal-Weight	N/A
Oct 30, 2026	Goldman Sachs	Buy	N/A
Oct 30, 2026	Morgan Stanley	Equal-Weight	N/A
Oct 30, 2026	Bernstein	Market Perform	N/A

Related Tools: Analyst Ratings Dashboard | View ALNY Stock Page